Aptevo Therapeutics (APVO) Other Operating Expenses (2017 - 2023)
Aptevo Therapeutics (APVO) posted Other Operating Expenses of $9.6 million for Q1 2023, down 32.7% sequentially from $14.3 million in Q1 2020.
Aptevo Therapeutics (APVO) Other Operating Expenses (2017 - 2023) Analysis & Trends
Aptevo Therapeutics has reported Other Operating Expenses for 3 years, with the latest figure at $9.6 million in Q1 2023.
- Quarterly Other Operating Expenses changed N/A year-over-year to $9.6 million in Q1 2023, while the trailing twelve-month figure through Dec 2023 was $9.6 million (changed N/A YoY) and the FY2023 annual result came in at $9.6 million, changed N/A from the prior year.
- Other Operating Expenses eased to $9.6 million in Q1 2023 per APVO's latest filing, from $14.3 million in the prior quarter.
- Over five years, Other Operating Expenses peaked at $14.3 million in Q1 2020 and troughed at $9.6 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Aptevo Therapeutics | 3.18 Mn | -6.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 9.65 Mn |
| Mar 31, 2020 | 14.34 Mn |
| Dec 31, 2017 | 159,000.00 |
| Sep 30, 2017 | 52.54 Mn |